Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors

Durham, NC (January 23, 2020) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary diseases, announced today that it has reached an agreement with Vertex Pharmaceuticals, Inc. to reacquire the pulmonary rights to epithelial sodium channel (ENaC) inhibitors developed under a collaboration announced between the parties in 2015. Under this … Continue reading Parion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors →